secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001213900-25-098702
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio CEO to present at Maxim Growth Summit on RDEB panel
--------------------------------------------------------------

- CEO David Moss will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on Oct 22, 2025.
- Panel to discuss CORDStrom platform for Recessive Dystrophic Epidermolysis Bullosa (RDEB) treatment.
- Summit takes place Oct 22-23 at Hard Rock Hotel, NYC; one-on-one meetings available.
- No financial or operational updates provided in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025098702/0001213900-25-098702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025098702/ea0260457-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-098702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer